
Vertex Pharmaceuticals (VRTX): CF Cash Engine Funds New Growth
Vertex is using its dominant cystic fibrosis franchise to fund expansion into gene editing, pain, and endocrinology. The stock looks fairly valued near consensus, making execution on ALYFTREK and new launches the key debate.










